RELEASE: TargEDys and SymbioPharm announce partnership for the launch of SymbioLife® Satylia® in Germany

(Information sent by the signatory company).

RELEASE: TargEDys and SymbioPharm announce partnership for the launch of SymbioLife® Satylia® in Germany

(Information sent by the signatory company)

LONGJUMEAU, France, Nov. 29, 2022 /PRNewswire/ -- TargEDys and SymbioPharm have signed an exclusive marketing agreement for the distribution of SymbioLife® Satylia® in Germany. This new dietary supplement made from the latest generation probiotic Hafnia alvei HA4597 will be available from January 2023.

SymbioLife® Satylia® is a precision probiotic with a mechanism of action characterized at the molecular level: it increases satiety thanks to the ClpB protein produced by Hafnia alvei HA4597. ClpB naturally mimics the satiety hormone alpha-MSH. Increased feeling of satiety contributes to successful weight loss, as confirmed by a clinical study conducted on 230 overweight adults. This natural principle provided by SymbioLife® Satylia® is a new, natural, safe and effective solution for weight management, which has received numerous awards.

Grégory Lambert, CEO of TargEDys: "We are very proud and excited about this new collaboration. SymbioPharm is in the top 3 of the German probiotics market and was the driving force behind one of the first probiotic pharmaceuticals worldwide. With a team with Their strong knowledge in probiotic Enterobacteria, their strong position with regard to physicians, pharmacies and synergies with probiotics and diagnostics, they are the perfect partner for this highly scientific product."

Juergen Eck, Co-CEO and CTO of SymbioPharm:

"We are very pleased to partner with TargEDys and work together in a new era of evidence-based probiotics. With the patented probiotic Hafnia alvei HA4597, its biological mechanism of action and outstanding studies, we can offer an effective solution for obesity problems. and metabolic health, increasingly prevalent. As pioneers in microbiome research and medical probiotics, we are proud to help shape the implantation of precision, knowledge-based probiotics."

About SymbioPharm

SymbioPharm GmbH has been a pioneer in microbiome and probiotic research since 1954. Its mission is to preserve health and cure disease with probiotic bacteria, taking advantage of the purely biological effect of natural bacteria. To do this, it investigates the human microbiome and develops innovative microbiological therapeutic approaches. The company has state-of-the-art production facilities and boasts extensive experience ranging from diagnostics, with the Institute of Microecology, to innovative solutions.

About TargEDys®

TargEDys® is a commercial phase French biotech company specializing in the development of nutraceutical solutions through interventions in the microbiome. He has 15 years of experience in microbiota research carried out in academic laboratories. TargEDys® develops a portfolio of products focused on overweight, malnutrition and mental health, all based on the concept of PreciBiomic strains supported by a molecular mechanism of action and in vivo studies.

Contact: Arnaud Faure

Logo -

View original content: